{"product_id":"gene-and-cellular-immunotherapy-for-cancer-9783030878511","title":"Gene and Cellular Immunotherapy for Cancer","description":"\u003cp\u003e\u003c\/p\u003e\u003cblockquote\u003e\n\u003cbr\u003eClinical and preclinical exploration of gene and cellular immunotherapy has seen rapid growth and interest, with five CAR-T products and one BiTE approved for lymphoma, myeloma, and ALL. This book provides a comprehensive review of current cellular and gene-based immunotherapies, focusing on CAR-T, TCR-T, TIL, Viral CTLs, NK cells, and T\/NK cell engagers. Edited by two leading experts, it will feature chapters written by recognized and up-and-coming experts. \u003c\/blockquote\u003e\u003cp\u003e\u003cstrong\u003eFormat\u003c\/strong\u003e: Paperback \/ softback\u003cbr\u003e\u003cstrong\u003eLength\u003c\/strong\u003e: 378 pages\u003cbr\u003e\u003cstrong\u003ePublication date\u003c\/strong\u003e: 21 December 2022\u003cbr\u003e\u003cstrong\u003ePublisher\u003c\/strong\u003e: Springer Nature Switzerland AG\u003cbr\u003e\u003c\/p\u003e \u003cp\u003e\u003cbr\u003eClinical and preclinical exploration of gene and cellular immunotherapy has witnessed a remarkable surge in growth and interest, fueled by the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma, as well as one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These groundbreaking advancements have significantly revolutionized the treatment of patients with relapsed refractory lymphoma, myeloma, and leukemia. Gene and Cellular Immunotherapy for Cancer presents readers with a comprehensive and detailed examination of current cellular and gene-based immunotherapies. Comprising eighteen cohesive chapters, this authoritative book delves into the realm of cellular-based immunotherapies, encompassing CAR-T, TCR-T, TIL, Viral CTLs, NK cells, and T\/NK cell engagers. It offers a thorough and insightful exploration of these therapies, focusing on their historical backgrounds, biological mechanisms, development processes, manufacturing challenges, toxicities, and other relevant aspects.\u003cbr\u003e\u003cbr\u003eEdited by two esteemed experts in the field of gene and cellular immunotherapy, this book features chapters authored by a diverse group of recognized and emerging experts and researchers. This diverse collection of contributions ensures that oncologists, immunologists, researchers, and clinical and basic science trainees gain a comprehensive and up-to-date perspective on the latest developments in this rapidly evolving field.\u003cbr\u003e\u003cbr\u003eThe chapters in Gene and Cellular Immunotherapy for Cancer are organized in a logical and coherent manner, allowing readers to easily navigate through the various topics. Each chapter begins with an introduction that provides a brief overview of the subject matter, followed by detailed explanations, case studies, and relevant references. The authors employ a multidisciplinary approach, drawing from their expertise in immunology, oncology, and other related disciplines, to provide a comprehensive understanding of the complexities of gene and cellular immunotherapy.\u003cbr\u003e\u003cbr\u003eOne of the key strengths of this book is its emphasis on providing a bench-to-bedside perspective. The authors not only delve into the theoretical aspects of these therapies but also discuss their clinical applications, including their efficacy, safety, and potential limitations. They provide real-world examples and case studies to illustrate the practical implications of these treatments and how they have transformed the lives of patients with cancer.\u003cbr\u003e\u003cbr\u003eFurthermore, the book includes comprehensive coverage of the latest developments in the field, including the use of CAR-T cells for solid tumors, the development of next-generation CAR-T cells, and the exploration of combination therapies with immunotherapy. The authors also address the challenges and ethical considerations associated with these therapies, such as immune-related adverse events, patient selection, and resource allocation.\u003cbr\u003e\u003cbr\u003eIn conclusion, Gene and Cellular Immunotherapy for Cancer is an essential resource for oncologists, immunologists, researchers, and clinical and basic science trainees seeking to stay abreast of the latest advancements in this field. With its comprehensive and detailed coverage, this book provides a valuable platform for understanding the biology, development, and clinical applications of gene and cellular immunotherapies. By presenting a bench-to-bedside perspective, it equips readers with the knowledge and skills necessary to translate these therapies into practice and improve the outcomes of patients with cancer.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eWeight\u003c\/strong\u003e: 593g\u003cbr\u003e\u003cstrong\u003eDimension\u003c\/strong\u003e: 235 x 155 (mm)\u003cbr\u003e\u003cstrong\u003eISBN-13\u003c\/strong\u003e: 9783030878511\u003cbr\u003e \u003cstrong\u003eEdition number\u003c\/strong\u003e: 1st ed. 2022\u003c\/p\u003e","brand":"Shulph Ink","offers":[{"title":"Paperback \/ softback","offer_id":44272401187066,"sku":"9783030878511","price":108.28,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0522\/4297\/2845\/products\/noImage_1_06aa5c7b-b50b-41bc-b230-4d80a8d9ab4c.jpg?v=1686253360","url":"https:\/\/shulphink.com\/products\/gene-and-cellular-immunotherapy-for-cancer-9783030878511","provider":"Shulph Ink","version":"1.0","type":"link"}